IL17A and infection: Furthermore, we reasoned that if the drug failed to improve disease outcome when given so early in the infection, our hypothesis would be thoroughly disproven and would negate the need for further investigation into the ideal therapeutic window and the appropriate dose range for inhibiting IL-17 production.